Medical Devices; Reclassification of the Topical Oxygen Chamber for Extremities; Correction, 29153 [2011-12410]
Download as PDF
<![CDATA[
Federal Register / Vol. 76, No. 98 / Friday, May 20, 2011 / Rules and Regulations
(ii) A statement that failure of a
counterparty to meet a collateral call
will result in an early termination event;
(iii) A description of early termination
pricing and methodology, with the
methodology reflecting a reasonable
estimate of the market value of the overthe-counter derivative contract at
termination (standard International
Swaps and Derivatives Association, Inc.
language relative to early termination
pricing and methodology may be used
to satisfy this requirement); and
(iv) A requirement that the Bank’s
consent be obtained prior to the transfer
of an agreement or contract by a
counterparty.
§ 1267.5 Risk-based capital requirements
for investments.
Any Bank which is not subject to the
capital requirements set forth in part
932 of this title shall hold retained
earnings plus general allowance for
losses as support for the credit risk of all
investments that are not rated by an
NRSRO, or are rated or have a putative
rating below the second highest credit
rating, in an amount equal to or greater
than the outstanding balance of the
investments multiplied by:
(a) A factor associated with the credit
rating of the investments as determined
by FHFA on a case-by-case basis for
rated assets to be sufficient to raise the
credit quality of the asset to the second
highest credit rating category; and
(b) 0.08 for assets having neither a
putative nor actual rating.
Dated: May 13, 2011.
Edward J. DeMarco,
Acting Director, Federal Housing Finance
Agency.
FDA is reclassifying the topical oxygen
chamber for extremities (TOCE) from
class III to class II. The document
published inadvertently used outdated
contact information. This document
corrects that error.
DATES: Effective May 25, 2011.
FOR FURTHER INFORMATION CONTACT:
Charles N. Durfor, Center for Devices
and Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. G424, Silver Spring,
MD 20993–0002, 301–796–6438.
SUPPLEMENTARY INFORMATION: In FR Doc.
2011–9899 appearing on page 22805 in
the Federal Register of Monday, April
25, 2011, the following correction is
made: 1. On page 22805, in the third
column, the FOR FURTHER INFORMATION
CONTACT section is corrected to read as
follows:
FOR FURTHER INFORMATION CONTACT: Charles
N. Durfor, Center for Devices and
Radiological Health, Food and Drug
Administration, Bldg. 66, Rm. G424, 10903
New Hampshire Ave., Silver Spring, MD
20993–0002, 301–796–6438.
Dated: May 17, 2011.
Nancy K. Stade,
Deputy Director for Policy, Center for Devices
and Radiological Health.
[FR Doc. 2011–12410 Filed 5–19–11; 8:45 am]
BILLING CODE 4160–01–P
ENVIRONMENTAL PROTECTION
AGENCY
40 CFR Part 52
[EPA–R09–OAR–2011–0030; FRL–9308–3]
Revisions to the California State
Implementation Plan, Mojave Desert
Air Quality Management District
[FR Doc. 2011–12358 Filed 5–19–11; 8:45 am]
BILLING CODE 8070–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Environmental Protection
Agency (EPA).
ACTION: Direct final rule.
Food and Drug Administration
SUMMARY:
AGENCY:
21 CFR Part 878
[Docket No. FDA–2006–N–0045; Formerly
Docket No. 2006N–0109]
Medical Devices; Reclassification of
the Topical Oxygen Chamber for
Extremities; Correction
emcdonald on DSK2BSOYB1PROD with RULES
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Final rule; correction.
The Food and Drug
Administration (FDA) is correcting a
final rule that appeared in the Federal
Register of April 25, 2011 (76 FR
22805). The document announced that
SUMMARY:
VerDate Mar<15>2010
15:03 May 19, 2011
Jkt 223001
EPA is taking direct final
action to approve revisions to the
Mojave Desert Air Quality Management
District (MDAQMD) portion of the
California State Implementation Plan
(SIP). These revisions concern negative
declarations for volatile organic
compound (VOC) source categories for
the MDAQMD. We are approving these
negative declarations under the Clean
Air Act as amended in 1990 (CAA or the
Act).
DATES: This rule is effective on July 19,
2011 without further notice, unless EPA
receives adverse comments by June 20,
2011. If we receive such comments, we
will publish a timely withdrawal in the
Federal Register to notify the public
PO 00000
Frm 00007
Fmt 4700
Sfmt 4700
29153
that this direct final rule will not take
effect.
ADDRESSES: Submit comments,
identified by docket number EPA–R09–
OAR–2011–0030, by one of the
following methods:
1. Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
on-line instructions.
2. E-mail: steckel.andrew@epa.gov.
3. Mail or deliver: Andrew Steckel
(Air-4), U.S. Environmental Protection
Agency Region IX, 75 Hawthorne Street,
San Francisco, CA 94105–3901.
Instructions: All comments will be
included in the public docket without
change and may be made available
online at https://www.regulations.gov,
including any personal information
provided, unless the comment includes
Confidential Business Information (CBI)
or other information whose disclosure is
restricted by statute. Information that
you consider CBI or otherwise protected
should be clearly identified as such and
should not be submitted through
https://www.regulations.gov or e-mail.
https://www.regulations.gov is an
‘‘anonymous access’’ system, and EPA
will not know your identity or contact
information unless you provide it in the
body of your comment. If you send
e-mail directly to EPA, your e-mail
address will be automatically captured
and included as part of the public
comment. If EPA cannot read your
comment due to technical difficulties
and cannot contact you for clarification,
EPA may not be able to consider your
comment.
Docket: The index to the docket for
this action is available electronically at
https://www.regulations.gov and in hard
copy at EPA Region IX, 75 Hawthorne
Street, San Francisco, California. While
all documents in the docket are listed in
the index, some information may be
publicly available only at the hard copy
location (e.g., copyrighted material), and
some may not be publicly available in
either location (e.g., CBI). To inspect the
hard copy materials, please schedule an
appointment during normal business
hours with the contact listed in the FOR
FURTHER INFORMATION CONTACT section.
FOR FURTHER INFORMATION CONTACT:
Cynthia Allen, EPA Region IX,
(415) 947–4120, allen.cynthia@epa.gov.
SUPPLEMENTARY INFORMATION:
Throughout this document, ‘‘we,’’ ‘‘us’’
and ‘‘our’’ refer to EPA.
Table of Contents
I. The State’s Submittal
A. What negative declarations did the State
submit?
B. Are there other versions of these
negative declarations?
E:\FR\FM\20MYR1.SGM
20MYR1
]]>Agencies
[Federal Register Volume 76, Number 98 (Friday, May 20, 2011)]
[Rules and Regulations]
[Page 29153]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-12410]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 878
[Docket No. FDA-2006-N-0045; Formerly Docket No. 2006N-0109]
Medical Devices; Reclassification of the Topical Oxygen Chamber
for Extremities; Correction
AGENCY: Food and Drug Administration, HHS.
ACTION: Final rule; correction.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is correcting a final
rule that appeared in the Federal Register of April 25, 2011 (76 FR
22805). The document announced that FDA is reclassifying the topical
oxygen chamber for extremities (TOCE) from class III to class II. The
document published inadvertently used outdated contact information.
This document corrects that error.
DATES: Effective May 25, 2011.
FOR FURTHER INFORMATION CONTACT: Charles N. Durfor, Center for Devices
and Radiological Health, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, Rm. G424, Silver Spring, MD 20993-0002, 301-
796-6438.
SUPPLEMENTARY INFORMATION: In FR Doc. 2011-9899 appearing on page 22805
in the Federal Register of Monday, April 25, 2011, the following
correction is made: 1. On page 22805, in the third column, the FOR
FURTHER INFORMATION CONTACT section is corrected to read as follows:
FOR FURTHER INFORMATION CONTACT: Charles N. Durfor, Center for
Devices and Radiological Health, Food and Drug Administration, Bldg.
66, Rm. G424, 10903 New Hampshire Ave., Silver Spring, MD 20993-
0002, 301-796-6438.
Dated: May 17, 2011.
Nancy K. Stade,
Deputy Director for Policy, Center for Devices and Radiological Health.
[FR Doc. 2011-12410 Filed 5-19-11; 8:45 am]
BILLING CODE 4160-01-P
